Critical Issues in Head and Neck Oncology
portes grátis
Critical Issues in Head and Neck Oncology
Key Concepts from the Eighth THNO Meeting
Leemans, C. Rene; Machiels, Jean-Pascal; O'Sullivan, Brian; Vermorken, Jan B.; Budach, Volker; Nicolai, Piero
Springer International Publishing AG
03/2023
365
Dura
Inglês
9783031231742
15 a 20 dias
Descrição não disponível.
The gut microbiota and anticancer immunotherapy, Laurence Zitvogel.- The bidirectional communication between tumor cells and other components of the tumor microenvironment, Phil Sloan.- Resistance mechanisms in immune checkpoint inhibitors and radiotherapy and how to overcome this, Kirsten Lauber.- DNA repair mechanisms as a new target in head and neck cancer, Kevin Harrington.- How to standardize molecular profiling programs for routine patient care, Ingeborg Tinhofer.- Novel immune oncology targets beyond PD-1/PD-L1 in head and neck cancer, Christophe Le Tourneau.- Analytic methods to understand head and neck cancer evolution to guide therapeutic approaches, Ben O'Leary.- Clinical cases, Jean Pascal Machiels.- Updates from the European Head & Neck Society (EHNS), Wojciech Golusinski (President of EHNS)Section 2: Primary disease Piero Nicolai.- Sensitivity and specificity of extranodal extension in SCCHN: unlocking the strongest prognostic factor in head and neckcancer, Brian O'Sullivan.- From photon to proton: what's in it for head and neck cancer patients?, Volker Budach.- Lessons learned from RTOG 1016 and DE-ESCALaTE: what's next?, Hisham Mehanna.-Treatment intensification in LA-SCCHN: what are the options and for who?, Jan Vermorken.- Immune checkpoint inhibitors in the curative setting: preclinical and clinical data, Jean-Pascal Machiels.- Carcinoma of unknown primary: diagnostics and the potential of transoral surgery, Rene Leemans.- Clinical cases, Volker Budach.- Individualized therapy in 1-line R/M-SCCHN: what selection criteria should we use?, Petr Szturz.- Patterns of response to immune oncology drugs: how relevant are they in SCCHN?, Amanda Psyrri.- The role of radiotherapy in oligometastatic or oligoprogressive disease in R/M-SCCHN, Daan Nevens.- Updates from the EORTC Head and Neck Cancer Group (HNCG), Jean-Pascal Machiels (Chair of EORTC-HNCG).- Real world evidence in head and neck cancer, Anil D'Cruz (UICC president.- Pathology driven treatment of skull base tumors, Piero Nicolai.- Modern day reconstruction of facial bones, Sat Parmar.- Targeting molecular/minimal residual disease using novel technologies and clinical trials design, Lillian Siu.- New developments in surgery for malignant salivary gland tumors, Jeroen Meulemans.- New systemic therapies in salivary gland cancer, Ethan Argiris. Exercise and nutrition interventions in head and neck cancer, Paolo Bossi.- Telehealth intervention in head and neck cancer patients: a promise?, Irma Verdonck-de Leeuw.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Open Access;Head and Neck Cancer;Predictive markers;Non-orophayngeal head and neck cancer;Induction chemotherapy;Radiation Oncology;Surgical Oncology;Liquid biopsies;Precision medicine;HNSCC;Nasopharynx cancer;Immunotherapy;Personalized Medicine
The gut microbiota and anticancer immunotherapy, Laurence Zitvogel.- The bidirectional communication between tumor cells and other components of the tumor microenvironment, Phil Sloan.- Resistance mechanisms in immune checkpoint inhibitors and radiotherapy and how to overcome this, Kirsten Lauber.- DNA repair mechanisms as a new target in head and neck cancer, Kevin Harrington.- How to standardize molecular profiling programs for routine patient care, Ingeborg Tinhofer.- Novel immune oncology targets beyond PD-1/PD-L1 in head and neck cancer, Christophe Le Tourneau.- Analytic methods to understand head and neck cancer evolution to guide therapeutic approaches, Ben O'Leary.- Clinical cases, Jean Pascal Machiels.- Updates from the European Head & Neck Society (EHNS), Wojciech Golusinski (President of EHNS)Section 2: Primary disease Piero Nicolai.- Sensitivity and specificity of extranodal extension in SCCHN: unlocking the strongest prognostic factor in head and neckcancer, Brian O'Sullivan.- From photon to proton: what's in it for head and neck cancer patients?, Volker Budach.- Lessons learned from RTOG 1016 and DE-ESCALaTE: what's next?, Hisham Mehanna.-Treatment intensification in LA-SCCHN: what are the options and for who?, Jan Vermorken.- Immune checkpoint inhibitors in the curative setting: preclinical and clinical data, Jean-Pascal Machiels.- Carcinoma of unknown primary: diagnostics and the potential of transoral surgery, Rene Leemans.- Clinical cases, Volker Budach.- Individualized therapy in 1-line R/M-SCCHN: what selection criteria should we use?, Petr Szturz.- Patterns of response to immune oncology drugs: how relevant are they in SCCHN?, Amanda Psyrri.- The role of radiotherapy in oligometastatic or oligoprogressive disease in R/M-SCCHN, Daan Nevens.- Updates from the EORTC Head and Neck Cancer Group (HNCG), Jean-Pascal Machiels (Chair of EORTC-HNCG).- Real world evidence in head and neck cancer, Anil D'Cruz (UICC president.- Pathology driven treatment of skull base tumors, Piero Nicolai.- Modern day reconstruction of facial bones, Sat Parmar.- Targeting molecular/minimal residual disease using novel technologies and clinical trials design, Lillian Siu.- New developments in surgery for malignant salivary gland tumors, Jeroen Meulemans.- New systemic therapies in salivary gland cancer, Ethan Argiris. Exercise and nutrition interventions in head and neck cancer, Paolo Bossi.- Telehealth intervention in head and neck cancer patients: a promise?, Irma Verdonck-de Leeuw.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
